Emibetuzumab
- Product Name
- Emibetuzumab
- CAS No.
- 1365287-97-3
- Chemical Name
- Emibetuzumab
- Synonyms
- LY2875358;Emibetuzumab;Emibetuzumab (anti-MET);Research Grade Emibetuzumab;Research Grade Emibetuzumab(DHC34201)
- CBNumber
- CB28080907
- Formula Weight
- 0
- MOL File
- Mol file
Emibetuzumab Property
- form
- Liquid
- color
- Colorless to light yellow
Emibetuzumab Chemical Properties,Usage,Production
Description
Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction, leading to MET internalization and degradation.
Uses
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].
Clinical Use
A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.
in vivo
Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice[1].
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice[1].
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models[1].
| Animal Model: | Athymic nude mice (U87MG tumor xenograft model)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection, once a week for 5 weeks. |
| Result: | Demonstrated a significant inhibition of tumor growth. |
| Animal Model: | Athymic nude mice (MKN45 xenograft tumor model)[1]. |
| Dosage: | 10 or 20 mg/kg |
| Administration: | Intravenous injection, single. |
| Result: | Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days. |
| Animal Model: | Athymic nude mice (MET-amplified xenograft mouse tumor models)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection, once a week for 3, 5 or 6 weeks. |
| Result: | Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors. |
References
[1] Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. DOI:10.1158/1078-0432.CCR-14-0543
Emibetuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Emibetuzumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 48457
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58